Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Verve Therapeutics

< Previous 1 2 Next >
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Publication of VERVE-101 Preclinical Data in Circulation and Presentations at the American Heart Association Annual Meeting
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pricing of Initial Public Offering
From Verve Therapeutics
Via Business Wire
Tickers VERV
Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors
From Verve Therapeutics
Via Business Wire
Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates
From Verve Therapeutics
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.